Wells Fargo Starts Allscripts (MDRX) at Market Perform; Long-term Growth Prospects Muted
Get Alerts MDRX Hot Sheet
Price: $4.90 -2%
Rating Summary:
8 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 19 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wells Fargo initiates coverage on Allscripts (NASDAQ: MDRX) with a Market Perform. PT range $10-12.
Analyst, Jamie Stockton, said, "The company provides software/services to about 24% of physicians working in a practice and about 5% of hospitals. Poor-quality software releases and disruptions in the company's sales/support organization drove a material March quarter miss. Management and board turnover have also been severe. While we believe trends are likely to improve as 2012 progresses, our long-term growth outlook suggests the shares are fairly valued. Strategic alternatives could see $14-16, but are unlikely near term."
For an analyst ratings summary and ratings history on Allscripts click here. For more ratings news on Allscripts click here.
Shares of Allscripts closed at $10.99 yesterday.
Analyst, Jamie Stockton, said, "The company provides software/services to about 24% of physicians working in a practice and about 5% of hospitals. Poor-quality software releases and disruptions in the company's sales/support organization drove a material March quarter miss. Management and board turnover have also been severe. While we believe trends are likely to improve as 2012 progresses, our long-term growth outlook suggests the shares are fairly valued. Strategic alternatives could see $14-16, but are unlikely near term."
For an analyst ratings summary and ratings history on Allscripts click here. For more ratings news on Allscripts click here.
Shares of Allscripts closed at $10.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AMD (AMD) to offer senior notes in four parts
- Leerink Starts Freenome Inc. (FRNM) at Outperform
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share